soria on Twitter: "#ENA2016 Dr seymour @theNCI @EORTC @aacr on iRECIST goals and limitations https://t.co/2TBUcpcndq" / Twitter
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
iRECIST: how to do it | Cancer Imaging | Full Text
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - ScienceDirect
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
EPOS™
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,
How to better understand iRECIST – a new wave in immunotherapeutic
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Cancers | Free Full-Text | Lights and Shadows in Immuno-Oncology Drug Development
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
How to better understand iRECIST – a new wave in immunotherapeutic
iRECIST: how to do it | Cancer Imaging | Full Text
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Assessing Immunotherapy Response and Progression
How to better understand iRECIST – a new wave in immunotherapeutic
The Radiology Assistant : RECIST 1.1 - and more
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
Présentation PowerPoint
